News and Events
Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer
Epic Sciences is collaborating with four major breast cancer centers on a clinical trial to determine if Epic’s blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage.
Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies
Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated.
Epic Sciences Announces Completion of $52 Million Series E Financing
Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR).
Calendar of Events
Society for Immunotherapy of Cancer 2018 Annual Meeting in Washington, D.C. from November 7 - 11, 2018.
European Society for Medical Oncology 2018 Congress in Munich, Germany from October 19 – October 23, 2018.
In the News
Video - New test extending lives of advanced prostate cancer patients
Bryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.
Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies
San Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.
Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium
New York, GenomeWeb – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.
Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer Diagnostic
San Diego, Clinical OMICs – Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.
Epic Sciences Continues Research on Multiple Fronts; Remains Quiet on Dx Development Pipeline
New York, GenomeWeb – With its first commercial diagnostic now fully launched and awaiting a final coverage decision by Medicare, Epic Sciences is keeping quiet about concrete plans for a pipeline of additional clinical assays, though it continues to collect data from research studies which may provide possibilities for future translation.
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.